Actively Recruiting
Feasibility and Preliminary Efficacy of a Digital Story Intervention to Facilitate Decision-Making in Patients With Myeloid Cancers Considering Allogeneic Hematopoietic Cell Transplantation
Led by University of Rochester · Updated on 2026-03-30
120
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating a digital story and values clarification intervention called CHORDS among patients with myeloid cancers who are considering allogeneic hematopoietic cell transplantation (alloHCT). This pilot randomized trial aims to assess the feasibility and preliminary effectiveness of CHORDS compared to usual care. The intervention is designed to help patients reflect on their emotions and priorities during decision-making about alloHCT treatment. The CHORDS intervention includes real-life digital stories from individuals and caregivers who previously underwent alloHCT consultation, along with explicit values clarification exercises. These exercises consist of an interactive workbook and best-worst scaling to help patients better understand treatment implications. Participants are randomly assigned to either the CHORDS intervention or usual care, with caregivers invited to participate when available. Usual care participants do not receive the CHORDS materials. Participants will complete baseline assessments before alloHCT consultation and follow-up assessments after the alloHCT office visit, including measures of decisional engagement, decisional conflict, and distress. The main outcome is the percentage of participants retained from enrollment to two weeks after the alloHCT visit. The study will monitor participant experiences and responses over this timeframe to evaluate the intervention's feasibility and impact.
CONDITIONS
Brief Title
Considering alloHCT: Opportunities for Patient Reflection During Decision-Making Via Digital Stories
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age over 21 years old
- Diagnosis of myeloid cancer including AML, MDS, myelofibrosis, CML, or MDS/MPN
- Considering allogeneic hematopoietic cell transplantation (alloHCT)
- Able to provide informed consent
- Able to speak English
You will not qualify if you...
- Psychiatric or cognitive conditions that prevent informed consent or compliance with study procedures as determined by hematologist
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - From enrollment (up to 30 days before) until the alloHCT office visit period (Day 9-19 post-transplant)
Participants randomized to the intervention arm engage with digital stories and values clarification exercises to help reflect on their emotions and clarify what matters to them regarding allogeneic hematopoietic cell transplantation.
Baseline visit and post-alloHCT office visits during Day 9-19
Duration - From enrollment (up to 30 days before) until the alloHCT office visit period (Day 9-19 post-transplant)
Participants randomized to usual care receive standard care and complete baseline and post-alloHCT office visit assessments without participating in the intervention.
Baseline visit and post-alloHCT office visits during Day 9-19
Trial Site Locations
Total: 1 location
1
University of Rochester
Rochester, New York, United States, 14642
Actively Recruiting
Research Team
R
Rachel Rodenbach, MD, MS
B
Becky Gravenstede, BA
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
SUPPORTIVE_CARE
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here